Streetbeat News

Analyst Ratings

MTTR

Piper Sandler analyst Brent Bracelin maintains a Neutral rating on Matterport (NASDAQ:MTTR) and raises the price target from $2 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:03 am

AYX

Piper Sandler analyst Brent Bracelin maintains an Underweight rating on Alteryx (NYSE:AYX) and raises the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:01 am

OLO

Piper Sandler analyst Clarke Jeffries has maintained an Overweight rating on Olo (NYSE:OLO) but lowered the price target from $10 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 8:59 am

UBER

Uber Technologies, Inc. (NYSE:UBER) is expected to report Q3 earnings of 12 cents per share, a significant improvement from a loss of 61 cents per share a year ago. Revenue is projected to be $9.52 billion, up from $8.12 billion in the same period last year. The company recently settled with the New York State Department of Labor to ensure eligible drivers and couriers can receive unemployment benefits. Uber's stock closed at $48.14 on Monday, up 0.8%. Several analysts have given the stock a 'Buy' rating with varying price targets.

Portfolio Pulse from Lisa Levin

November 07, 2023 | 7:40 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) stock has been experiencing a decline, with Morgan Stanley analyst Adam Jonas suggesting a 4-point plan to reverse the trend. The plan includes avoiding earnings disappointment, expanding models, expanding the total addressable market, and changing the narrative. Jonas maintains an Overweight rating and a $380 price target for the stock, indicating a 74% upside from current levels. He also estimates Tesla’s on-the-road-fleet will reach 34 million units by 2030, 69 million units by 2035, and 117 million units by 2040.

Portfolio Pulse from Shanthi Rexaline

November 07, 2023 | 6:20 am

CPRT

PLTR

SOFI

UEC

Jim Cramer, the host of CNBC’s Lightning Round, has expressed his support for Palantir Technologies Inc., indicating a shift in his previous opinion. He also expressed positivity towards SoFi Technologies Inc., Uranium Energy Corp., Copart, Inc., and the Blackstone Group Inc., while voicing his displeasure with BP PLC.

Portfolio Pulse from Benzinga Neuro

November 07, 2023 | 6:20 am

BTCUSD

DOGEUSD

ETHUSD

Major cryptocurrencies including Bitcoin, Ethereum, and Dogecoin experienced a surge on Monday evening, driven by the anticipation that the Federal Reserve may halt its rate hikes due to weaker U.S. jobs data. The global crypto market cap currently stands at $1.32 trillion. Stocks also continued their upward momentum on Monday, with the Nasdaq Composite, S&P 500, and Dow Jones Industrial Average all making gains. Crypto analysts suggest that Bitcoin may be poised for an unexpected bull run that could extend into the next year.

Portfolio Pulse from Mehab Qureshi

November 07, 2023 | 2:54 am

CELH

HIMS

LIFW

TSLA

UBER

Five stocks have caught investors' attention: MSP Recovery, Uber, Hims & Hers Health, Celsius, and Tesla. MSP Recovery surged 252.19% after confirming compliance with Nasdaq listing standards. Uber rose slightly by 0.82% due to strong demand in the mobility and delivery market. Hims & Hers Health dipped by -3.09% despite raising its full-year revenue guidance and announcing a $50 million share buyback program. Celsius climbed 1.35% ahead of its earnings report and news of a three-for-one stock split. Tesla declined by -0.31% but is expected to rally due to new vehicle plans and wage increases at its German factory.

Portfolio Pulse from Benzinga Neuro

November 07, 2023 | 2:26 am

ORIC

ORIC Pharmaceuticals reported Q3 losses of $(0.44) per share, beating the analyst consensus estimate of $(0.46) by 4.35 percent. This represents a 12 percent improvement over losses of $(0.50) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:45 pm

IVA

Inventiva (NASDAQ:IVA) has announced that its lead compound, Lanifibranor, will be the subject of a late breaker abstract and two additional abstracts at the AASLD The Liver Meeting 2023. The abstracts will present results from phase II trials evaluating Lanifibranor in patients with T2D and MASLD, and patients with NASH. The results show a correlation between the increase of adiponectin under Lanifibranor and the improvement of histological and serum markers of NASH severity. The efficacy of Lanifibranor appears to be independent of PNPLA3 status.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:30 pm